There are no major negatives other than the well-known patent expirations looming for some of NVS’ big-selling drugs. The 2Q10 PR and CC slides are a good place to start to get acquainted with NVS’ portfolio of products and businesses: #msg-52296278, #msg-52297255.
Market Data 
Markets 
AI
